Gubra (One-pager): Enters 2026 with three differentiated obesity candidates — pivotal data readouts expected in 2026
Oversigt
- In 2025, Gubra achieved revenue of DKK 2.6bn and an operating profit of DKK 2.2bn, largely due to an out-licensing agreement with AbbVie for ABBV-295, which included a USD 350m upfront payment.
- Gubra is transitioning from an obesity-focused biotech to a diversified life science company, with plans to establish new therapeutic areas by 2030 and expand its CRO platform into areas like sarcopenia and women’s health.
- Entering 2026, Gubra has three differentiated obesity candidates, with pivotal data readouts expected; ABBV-295 and UCN2 are key assets with upcoming clinical milestones that could enhance their market success probabilities.
- Gubra's strong capital position reduces the risk of dilutive capital raises, but clinical risks remain, as future earnings depend on partners AbbVie and Boehringer Ingelheim advancing the programs.
This content is generated by AI. You can give feedback on it in the Inderes forum.
2025 was a pivotal year for Gubra, with revenue of DKK 2.6bn and operating profit of DKK 2.2bn, driven by the landmark out-licensing agreement with AbbVie for the long-acting amylin analogue ABBV-295, with USD 350m in upfront payment, and DKK 1.1bn well-positioned to drive further development
2025 also marked the beginning of a broader transformation evolving from an obesity-focused biotech into a broader, more diversified life science company, with the new Ventures unit set to incubate focused companies in therapeutic areas beyond the core pipeline, with the first venture planned for H2 2026. The company has announced ambitions to establish new flagship therapeutic areas beyond obesity by 2030, and the CRO platform is expanding into new service areas, including sarcopenia and women’s health.
Gubra enters 2026 with three clinical obesity candidates, each designed to differentiate in a market where there are some indications that investors are slowly starting to shift their focus away from efficacy to also look at treatment quality. ABBV-295 (AbbVie) differentiates on tolerability and convenient once-weekly dosing. BI 3034701 (Boehringer Ingelheim) is a first-in-class triple agonist now advancing to mid-stage clinical development. UCN2 addresses the market’s new focal point directly: via the CRHR2 receptor, the candidate reduces fat mass while preserving or increasing muscle mass, in contrast to current standard-of-care treatments, where up to 45% of weight loss derives from lean body mass.
2026 is shaping up to follow in the footsteps of 2025, being pivotal with very important data readouts. AbbVie has expressed expectations to publish MAD study data for ABBV-295 and has signaled the initiation of Phase II in 2026. For UCN2, the clinical trial application has now been submitted to the health authorities, with the first patient expected to be dosed in H1 2026, which could give further clarification through the study design. Further details on the timeline will be presented at the R&D Day on 30 June.
ur one-pager investment pager focus on a company description, investment case, key risks, financial highlights, and a pipeline overview.
Our DCF scenario analysis shows a market-implied probability of success (PoS) of approximately 23% in the base case — around the historical Phase I benchmark of 26% for obesity peptides — with the upcoming clinical milestones for ABBV-295 and UCN2 representing the primary catalysts for value creation through derisking and increasing the probabilities of success. Gubra’s strong capital position materially reduces the risk of dilutive capital raises and sets the company apart from most early-stage biotech peers.
The risk includes clinical risk: both ABBV-295 and UCN2 are early-stage clinical assets with no guarantee of clearing all clinical and regulatory hurdles. A significant share of Gubra’s future earnings also depends on partners AbbVie and Boehringer Ingelheim continuing to prioritize and advance the programs.
Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate visibility subscription agreement / Michael Friis 08:30 09/03/2026, updated 10:30 09/03/2026